Jpmorgan Chase & CO Immatics N.V. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$68.5 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$66.3 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$55.4 Million2.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.38MShares$50.6 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$44.1 Million0.79% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $522M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...